Merck & Co., Inc. Marketable Securities (Current)
Merck & Co., Inc. (MRK) had Marketable Securities (Current) of $292.00 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-07
- 2026-06-30: Marketable Securities, Current $292.00M.
- 2026-03-31: Marketable Securities, Current $375.00M.
- 2025-12-31: Marketable Securities, Current $0.00.
- 2025-09-30: Marketable Securities, Current $45.00M.
| Period end | Marketable Securities, Current | Marketable Securities, Current as first filed |
|---|---|---|
| 2026-06-30 | $292.00M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $375.00M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $45.00M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $615.00M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $599.00M 10-Q · filed 2025-05-02 | |
| 2024-12-31 | $447.00M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $50.00M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $40.00M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $252.00M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $168.00M 10-Q · filed 2023-11-03 | |
| 2022-12-31 | $498.00M 10-K · filed 2024-02-26 | |
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $7.00M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $774.00M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $149.00M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $446.00M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $722.00M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $899.00M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $2.46B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $2.28B 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $2.86B 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $2.41B 10-K · filed 2019-02-27 | |
| 2017-09-30 | $3.29B 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $4.18B 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $3.54B 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $7.83B 10-K · filed 2018-02-27 | |
| 2016-09-30 | $5.16B 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $5.23B 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $3.23B 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $4.90B 10-K · filed 2017-02-28 | |
| 2015-09-30 | $4.54B 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $4.45B 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $7.62B 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $8.28B 10-K · filed 2016-02-26 | |
| 2014-09-30 | $2.98B 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $3.65B 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $4.68B 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $1.86B 10-K · filed 2015-02-27 | |
| 2013-09-30 | $4.08B 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $3.01B 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $3.00B 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $2.69B 10-K · filed 2014-02-27 | |
| 2012-09-30 | $757.00M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $698.00M 10-Q · filed 2012-08-07 | |
| 2012-03-31 | $910.00M 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $1.44B 10-K · filed 2013-02-28 | |
| 2011-09-30 | $1.32B 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $1.64B 10-Q · filed 2011-08-08 | |
| 2011-03-31 | $1.33B 10-Q · filed 2011-05-09 | |
| 2010-12-31 | $1.30B 10-K · filed 2012-02-28 | |
| 2010-09-30 | $750.40M 10-Q · filed 2010-11-08 | |
| 2010-06-30 | $1.28B 10-Q · filed 2010-08-06 | |
| 2010-03-31 | $1.54B 10-Q · filed 2010-05-07 | |
| 2009-12-31 | $293.00M 10-K · filed 2011-02-28 | $293.10M 10-K · filed 2010-03-01 |
| 2008-12-31 | $1.12B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |